See how Hyperion Therapeutics is improving patients’ lives.

Read more »

Stay informed HCP

Mon, 02/04/2013 - 20:13 -- admin

By telling us about your experience with urea cycle disorders (UCDs), we can provide you with information, news, and resources that are relevant to you and your patients.

Our focus: saving, extending, and improving patients’ lives

Hyperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company committed to advancing science and developing treatments for orphan and hepatic diseases. RAVICTI® (glycerol phenybutyrate) Oral Liquid is our first approved product for the treatment of urea cycle disorders (UCDs). Hyperion therapeutics also markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder for UCDs and is developing glycerol phenylbutyrate for hepatic encephalopathy related to severe hepatic disease.

The THRIVE Registry

THRIVE is a long-term urea cycle disorder (UCD) patient registry that helps the scientific and medical communities advance the understanding and treatment of UCDs.

Read about the THRIVE Registry or call 1-855-UCD-2595 (1-855-823-2595).

Latest news

Read about Hyperion Therapeutics in industry-related news.

Hyperion Therapeutics and Clal Biotechnology Industries Ltd. Enter Into Interim Agreement

UCD Patient Stories